AstraZeneca finalises $520 million settlement in Seroquel off-label probe
This article was originally published in Scrip
Executive Summary
AstraZeneca has finalised a previously announced $520 million payout to settle federal allegations that it marketed its antipsychotic Seroquel (quetiapine fumarate) for unapproved uses. The company has resolved civil allegations brought by the Department of Justice under the US False Claims Act and will not face criminal charges.